Report Overview

The China diabetes drug market size stood at around USD 4.84 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

China has the largest number of diabetic patients in the world and has the fastest increase in the prevalence of diabetes. Approximately 114.4 million people in China are affected by diabetes. The Government of China is introducing numerous healthcare reforms, which are bolstering the market growth. For instance, it is encouraging foreign investments and allowing multinational companies (MNCs) to offer their services in the country. This has enabled patients to diagnose diabetes at the nascent stage and manage it properly.



Market Drivers

Chinese people are genetically more vulnerable to diabetes as compared to Europeans. Apart from this, unawareness about health issues, significant consumption of white rice, and poor healthcare infrastructure represent the prominent factors driving the incidences of diabetes. Prominent drug manufacturers in China are focusing on increasing their budget for research and development (R&D) activities to create innovative drugs. This trend, in confluence with the highly developed pharmaceutical industry, is contributing to the market growth in the country. Apart from this, a sedentary lifestyle clubbed with the intake of an unhygienic diet significantly contributes to the increased number of diabetic cases in the country.